Ahmed Sayed

jacc.org/doi/10.1016/j.… Confirming and quantifying what was suspected - heart failure is evolving. Significant evidence generation implications.

Original Article: Beta-blockers after Myocardial Infarction with Normal Ejection Fraction nej.md/43U5Ppo @AHAScience | #AHA25

🙏🙏Immensely grateful for the generous support and guidance from Dr. Ann Marie Navar, @virani_md, @ericpetersonMD, and @dramitkhera 🙏🙏 And many thanks to @JAMAInternalMed for offering an avenue to share our findings

How does the move to PREVENT for ASCVD risk estimation affect aspirin use❓ 📜jamanetwork.com/journals/jamai… 1⃣ >80% eligible for 1ry prevention aspirin based on a PCE risk >10% would no longer be eligible w/ PREVENT 2⃣ Most current aspirin users don't qualify under either calculator

Biggest move today in clinic: Stopping ASA in pts on DOAC AQUATIC = most important trial of the year. medscape.com/viewarticle/aq…

Here are my takeaways for the 7 most relevant and important #ESCCongress2025 for generalists AQUATIC, HI-PRO, RETREAT-FRAIL, DIGIT-HF, DAN-RSV were most practicing changing POTCAST was most contentious - not as billed

🙏Incredibly grateful to @almallahmo for supervision , @MalekNayfeh, Fares AlAhdab, Mahmoud Al Rifai, @DmitryAbramovMD, @FudimMarat , @YasMoayedi, @RayanYousefzai for their incredible support, and to @JACCJournals CV imaging for the opportunity to publish our work🙏

Do heart transplant patients always need invasive angio to screen for graft vasculopathy❓ 📜authors.elsevier.com/a/1lWfA,i2Xs0R… In this meta-analysis, CTA/PET had pretty respectable sensitivity/NPV for ruling out graft vasculopathy compared to a gold standard of invasive angiography.

NEW PAPER in @bmj_latest "Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide" --> bmj.com/content/390/bm… #methodologymatters

Over the past 41 years, death due to ischemic heart disease did not decline in countries with low socioeconomic development, research shows @ASayedMD @MethodistHosp @virani_md @ErinMichos @annmarienavar @DrLaPrincess ahajrnls.org/3EWOnYl

🙏🙏Incredibly thankful to @almallahmo and Dr. Al Rifai for their supervision & guidance on this; and to my brilliant colleague @MariaAlwan_ 🙏🙏 And thank you to @EHJCVIEiC for allowing us to share our findings!

Patients with a normal-ish EF could be further stratified as being at a *truly* low-risk of events or at intermediate risk depending on their rest flow. In contrast, patients with a depressed EF had a uniformly high rate of events regardless.

1/4🧵 In patients undergoing cardiac stress testing w/ PET, does rest flow matter❓ In an analysis of >8k patients, we find that it does, esp. in patients with a preserved EF. Link📜: doi.org/10.1093/ehjci/… @almallahmo @MariaAlwan_ @MyASNC @MethodistHosp @EHJCVIEiC

𝐃𝐒𝐄 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐢𝐧 𝐎𝐑𝐁𝐈𝐓𝐀-𝟐: Stress echo ischemia identifies who 𝘳𝘦𝘢𝘭𝘭𝘺 benefits from PCI. 📖 𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐢𝐧 #𝐉𝐀𝐂𝐂: bit.ly/42PNCcB @rallamee @mshunshin @rajkumar_chris @MikeFoley89 @FloSimader @ShaynaChotai

An incredible experience at #DDW2025! Privileged to share our work on #pancreaticcancer, Fatty Pancreas, and #colorectalcancer With 3 oral presentations, and 3 poster presentations ✅ Immensely grateful for the mentorship and support of Dr. @SriGaddamMD 🙏🏼

New genetic analysis in 200k people over 14 years ▶️apoB + lp(a) best capture lipid-mediated CV risk ▶️LDL particle size adds no additional info when apoB is accounted for academic.oup.com/eurheartj/adva…

Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with autoimmune or inflammatory diseases. @AndreZimerman @bweber04 @analaurakunzler @rgiuglaino ahajournals.org/doi/full/10.11…

Just in time for #HRS2025‼️ Excited to share our latest paper published in @AmericanHeartJ and honored to be first co-author with Dr. Bockus. Looking forward to presenting our work in San Diego. sciencedirect.com/science/articl… @NazemAkoum @UWMedHeart